OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLCT. Owonikoko,M. Boyer,M. Johnson,R. Govindan,L. Rodrigues,F. Blackhall,R. Boosman,S. Champiat, H. Hummel, W.V. Lai,H. Udagawa, A. Chiang,A. Dowlati,C. Hann,R. Salgia,E. Vokes,M. Minocha,N. Sadraei,A. Shetty,M. SmitJournal of Thoracic Oncology（2021）引用 3|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
